Ricin Toxin

Author(s): Wei-Gang Hu, Junfei Yin, Damon Chau, Charles C. Hu and John W. Cherwonogrodzky

DOI: 10.2174/9781608058785114010012

Anti-Ricin Protective Monoclonal Antibodies

Pp: 145-158 (14)

Buy Chapters
  • * (Excluding Mailing and Handling)

Abstract

SHS investigation development is considered from the geographical and historical viewpoint. 3 stages are described. Within Stage 1 the work was carried out in the Department of the Institute of Chemical Physics in Chernogolovka where the scientific discovery had been made. At Stage 2 the interest to SHS arose in different cities and towns of the former USSR. Within Stage 3 SHS entered the international scene. Now SHS processes and products are being studied in more than 50 countries.

Abstract

Development of anti-ricin protective monoclonal antibodies (mAbs) started in the early 1980s. Much progress has been made since then. Antibodies possess great potential for development as antidotes against toxins. These can be used either prophylactically to prevent, or therapeutically to treat, toxin-mediated intoxications in an emergency situation. Unlike many other therapeutic products, antibodies offer unique and high target specificity, and long half-life in serum. There are several mAbs which are currently in the discovery stage for medical countermeasures against ricin intoxication. This review summarizes these mAbs, including their anti-ricin mechanism, generation, and efficacies in vivo.

Recommended Chapters

We recommend

Favorable 70-S: Investigation Branching Arrow

Authors:Bentham Science Books